Azacitidine

multilineage dysplasia, induction chemotherapy, Anemia, Refractory + 11 more

Treatment

4 FDA approvals

20 Active Studies for Azacitidine

What is Azacitidine

Azacitidine

The Generic name of this drug

Treatment Summary

Azacytidine is a medication used to treat cancer by blocking the action of an enzyme involved in DNA methylation. It is also used as an antimetabolite of cytidine, which is incorporated into RNA. Azacytidine is an antineoplastic drug, meaning that it is used to stop the growth of cancer cells.

Vidaza

is the brand name

image of different drug pills on a surface

Azacitidine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vidaza

Azacitidine

2004

34

Approved as Treatment by the FDA

Azacitidine, commonly known as Vidaza, is approved by the FDA for 4 uses like multilineage dysplasia and Leukemia, Myeloid, Acute .

multilineage dysplasia

Leukemia, Myeloid, Acute

Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Effectiveness

How Azacitidine Affects Patients

Azacitidine works by decreasing the methylation of DNA, which can restore normal function to genes that are important for cell growth and differentiation. It also causes the death of cells that are no longer responding to normal growth control mechanisms. After it is taken up by cells, it is converted into different forms that disrupt nuclear and cytoplasmic RNA metabolism and inhibit protein synthesis, as well as stop DNA synthesis. Azacitidine is most effective when cells are in the S-phase of the cell cycle.

How Azacitidine works in the body

Azacitidine helps fight cancer by blocking DNA from being made. At low doses, it prevents DNA from being methylated, which is necessary for it to be made. At high doses, it gets incorporated into both DNA and RNA, stopping the cells from being able to produce the proteins needed for cell growth and survival, eventually leading to cell death.

When to interrupt dosage

The measure of Azacitidine is contingent upon the diagnosed malady, including induction chemotherapy, 20-30% blasts and Anemia. The dosage is dependent on the technique of delivery (e.g. Subcutaneous or Tablet - Oral) detailed in the table below.

Condition

Dosage

Administration

Acute Myeloid Leukemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Complete Remission

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Anemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

multilineage dysplasia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Leukemia, Myeloid, Acute

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Blood Transfusion

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

induction chemotherapy

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Complete Blood Count

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Anemia, Refractory

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Chronic Myelomonocytic Leukemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Anemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Malignant Neoplasms

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

neutropenia and/or thrombocytopenia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Anemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

, Subcutaneous, Powder, for suspension - Subcutaneous, Powder, for suspension, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Subcutaneous, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet, Tablet - Oral

Warnings

Azacitidine Contraindications

Condition

Risk Level

Notes

Liver Neoplasms

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Azacitidine may interact with Pulse Frequency

There are 20 known major drug interactions with Azacitidine.

Common Azacitidine Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with Abatacept.

Abetimus

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with Acteoside.

Azacitidine Toxicity & Overdose Risk

A patient experienced diarrhea, nausea, and vomiting after taking a large dose of azacitidine. This was almost 4 times the recommended starting dose and the equivalent of 290 mg/m2.

image of a doctor in a lab doing drug, clinical research

Azacitidine Novel Uses: Which Conditions Have a Clinical Trial Featuring Azacitidine?

367 active studies are currently being conducted to determine the efficacy of Azacitidine in treating Chronic Myelomonocytic Leukemia, Blood Transfusion and multilineage dysplasia.

Condition

Clinical Trials

Trial Phases

Acute Myeloid Leukemia

267 Actively Recruiting

Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1

Complete Remission

0 Actively Recruiting

Chronic Myelomonocytic Leukemia

54 Actively Recruiting

Phase 1, Phase 2, Phase 3, Early Phase 1

Anemia, Refractory

0 Actively Recruiting

Blood Transfusion

0 Actively Recruiting

induction chemotherapy

0 Actively Recruiting

Complete Blood Count

0 Actively Recruiting

Anemia

0 Actively Recruiting

Anemia

0 Actively Recruiting

neutropenia and/or thrombocytopenia

0 Actively Recruiting

Leukemia, Myeloid, Acute

0 Actively Recruiting

Malignant Neoplasms

0 Actively Recruiting

Anemia

0 Actively Recruiting

multilineage dysplasia

0 Actively Recruiting

Azacitidine Reviews: What are patients saying about Azacitidine?

4

Patient Review

5/5/2017

Azacitidine for Bone Marrow Disorders Occurring Before Leukemia

This treatment was really effective. My hemoglobin count went from 6.2 to 17 after six treatments.

3.3

Patient Review

1/27/2010

Azacitidine for Bone Marrow Disorders Occurring Before Leukemia

I developed large lumps under my skin and felt itchiness and pain on my left side. The injection was inserted in the fatty tissue above my belly button.

1.7

Patient Review

7/19/2016

Azacitidine for Bone Marrow Disorders Occurring Before Leukemia

My mother was given this treatment three times and had terrible side effects each time, eventually leading to her death from renal failure caused by extreme diarrhea.

1.3

Patient Review

8/25/2013

Azacitidine for Bone Marrow Disorders Occurring Before Leukemia

I have MDS. This treatment didn't work for me, so the medical model says I'm out of options.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about azacitidine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is azacitidine?

"Azacitidine is a cancer medication that works by killing abnormal cells in the bone marrow, as well as by helping the bone marrow to produce normal blood cells."

Answered by AI

Is azacitidine a chemotherapy?

"Azacitadine is a chemotherapy drug that works by killing cancer cells. It is classified as an antimetabolite and a demethylating agent."

Answered by AI

What is the drug azacitidine used for?

"Azacitidine injection is used to treat patients with French-American-British (FAB) myelodysplastic syndrome (bone marrow problem) subtypes, including refractory anemia or chronic leukemia. This medicine is also used to treat juvenile myelomonocytic leukemia (JMML)."

Answered by AI

How long can you take azacitidine?

"We recommend that patients be treated with azacitidine for a minimum of 6 months, and that in patients who achieve a response or stable disease, treatment be continued until disease progression or unacceptable toxicity occurs."

Answered by AI

Clinical Trials for Azacitidine

Image of University of California Davis Comprehensive Cancer Center in Sacramento, United States.

Olutasidenib + Azacitidine for Acute Myeloid Leukemia

18+
All Sexes
Sacramento, CA

This phase II trial studies how well giving olutasidenib with azacitidine, followed by olutasidenib maintenance, works in treating patients with IDH1-mutated acute myeloid leukemia (AML) who have received prior treatment with venetoclax plus a hypomethylating agent (HMA-Ven). Olutasidenib and azacitidine may inhibit the growth of cancer cells by blocking certain enzymes required for cell growth. Maintenance therapy can help prevent or delay cancer from coming back. Olutasidenib with azacitidine followed by olutasidenib maintenance may be effective in treating patients with IDH1-mutated AML who have received prior HMA-Ven.

Phase 2
Recruiting

University of California Davis Comprehensive Cancer Center

Brian Jonas, MD

Image of University of Virginia in Charlottesville, United States.

CD33 FPBMC for Acute Myelogenous Leukemia

18+
All Sexes
Charlottesville, VA

The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) where they still have detectable disease ("MRD+") after some treatment. Participants receive 4 weekly doses of CD33 FPBMC by intravenous infusion followed by 4-6 weeks of standard treatment with a hypomethylating agent (type of treatment such as decitabine or azacitidine) and possibly a drug called venetoclax. This is considered 1 cycle of study treatment and may be repeated up to 4 times during the study.

Phase 1
Recruiting

University of Virginia

Daniel Reed, MD

Image of The University of Arizona Cancer Center in Tucson, United States.

DLI-X for Leukemia

Any Age
All Sexes
Tucson, AZ

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. Additionally, the study aims to assess the safety and efficacy of therapeutic DLI-X (t-DLI-X) compared to t-DLI alone in patients with minimal residual disease (MRD+) or overt relapse post-alloHCT. For patients with CD19-positive lymphoid malignancies, the study will incorporate blinatumomab, while those with myeloid or CD19-negative lymphoid malignancies will receive t-DLI-X or t-DLI alone. We hypothesize that both pro-DLI-X and t-DLI-X, with or without blinatumomab, will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).

Phase 1
Waitlist Available

The University of Arizona Cancer Center

Emmanuel Katsanis, MD

Have you considered Azacitidine clinical trials?

We made a collection of clinical trials featuring Azacitidine, we think they might fit your search criteria.
Go to Trials
Image of OHSU Knight Cancer Institute in Portland, United States.

Fludarabine + Cytarabine + Idarubicin + Venetoclax for Acute Myeloid Leukemia

18 - 65
All Sexes
Portland, OR

This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.

Phase 2
Waitlist Available

OHSU Knight Cancer Institute

Curtis A Lachowiez

Image of Brigham and Women's Hospital in Boston, United States.

Tagraxofusp + Venetoclax + Azacitidine for Acute Myeloid Leukemia

18+
All Sexes
Boston, MA

The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence. The names of the study drugs involved in this study are: * Tagraxofusp (a type of CD123-directed cytotoxin) * Azacitidine (a type of standard of care cytidine nucleoside analog) * Venetoclax (a type of standard of care BCL-2 inhibitor)

Phase 1 & 2
Recruiting

Brigham and Women's Hospital (+1 Sites)

Jacqueline Garcia, MD

Stemline Therapeutics, Inc.

Have you considered Azacitidine clinical trials?

We made a collection of clinical trials featuring Azacitidine, we think they might fit your search criteria.
Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Treatment Intensity for Acute Myeloid Leukemia

18+
All Sexes
Seattle, WA

This clinical trial studies whether less fit adults with acute myeloid leukemia (AML) or myeloid neoplasms are willing to let a computer program decide (randomization) whether they receive lower- or higher-intensity chemotherapy. Historically, treatment decision-making for patients with AML or myeloid neoplasms has divided patients into two categories, with patients considered fit receiving intensive "curative" chemotherapy, and patients considered unfit, such as older patients with a higher risk of early death from therapy, receiving non-intensive "palliative" therapy or no therapy. With the introduction of new treatment agents, it has become difficult to determine the difference between intensive and non-intensive therapy, especially for patients considered unfit for whom treatment-related side effects remain a concern. Treatment intensity is best identified through randomized trials but often patients are unwilling to undergo randomization due to preset beliefs. However, with improved supportive care and the awareness that new treatment agents may have similar risks as intensive therapy, it may be possible that more patients are willing to be randomized. This may help identify the best treatment intensity for less fit adults with AML or myeloid neoplasms, which may improve outcomes.

Waitlist Available
Has No Placebo

Fred Hutch/University of Washington Cancer Consortium

Jacob Appelbaum, MD, PhD

Image of Houston Methodist Neal Cancer Center in Houston, United States.

Hypomethylating Agents vs. Intensive Chemotherapy for Acute Myeloid Leukemia

18+
All Sexes
Houston, TX

This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA)-for assessing measurable residual disease (MRD) in patients with newly diagnosed acute myeloid leukemia (AML). The study compares the efficacy of hypomethylating agent (HMA)-based therapy versus intensive induction chemotherapy, using the 5hmC biomarker to guide post-induction treatment decisions. Approximately 112 adult patients will be enrolled and assigned to treatment arms based on a stratified sampling scheme. Blood samples will be collected at defined intervals to assess MRD status. Primary endpoints include minimal residual disease (MRD) negativity rate, duration of remission, event-free survival (EFS), and overall survival (OS).

Phase 2
Waitlist Available

Houston Methodist Neal Cancer Center

Shilpan Shah, MD

Image of Texas Children's Cancer and Hematology Center in Houston, United States.

Combination Therapy for Pediatric Acute Myeloid Leukemia

1 - 30
All Sexes
Houston, TX

This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at intermediate-risk (IR) and high-risk (HR) of relapse. The goal is to achieve similar or better survival with chemotherapy cycles that are intensive but less likely to cause long-term complications. Patients will enroll on this trial at the end of their first induction cycle. The two cycles to be substituted are: * "Ida-FLA" (idarubicin+fludarabine/cytarabine) as Induction 2 * "VIA" (venetoclax+idarubicin+cytarabine) as Intensification 1 of the HR treatment regimen, and Intensification 2 of the IR treatment backbone. Researchers will evaluate side effects and outcomes for up to three years after enrollment. Participants will also have the opportunity to participate in optional research studies including patient surveys and blood and bone marrow sample testing.

Phase < 1
Recruiting

Texas Children's Cancer and Hematology Center

Have you considered Azacitidine clinical trials?

We made a collection of clinical trials featuring Azacitidine, we think they might fit your search criteria.
Go to Trials